Cancers, Vol. 16, Pages 1580: T-Cell Engagers & mdash;The Structure and Functional Principle and Application in Hematological Malignancies

Cancers, Vol. 16, Pages 1580: T-Cell Engagers—The Structure and Functional Principle and Application in Hematological Malignancies Cancers doi: 10.3390/cancers16081580 Authors: Paweł Cech Katarzyna Skórka Laura Dziki Krzysztof Giannopoulos Recent advancements in cancer immunotherapy have made directing the cellular immune response onto cancer cells a promising strategy for the treatment of hematological malignancies. The introduction of monoclonal antibody-based (mAbs) targeted therapy has significantly improved the prognosis for hematological patients. Facing the issues of mAb-based therapies, a novel bispecific antibody (BsAb) format was developed. T-cell engagers (TCEs) are BsAbs, which simultaneously target tumor-associated antigens on tumor cells and CD3 molecules present on T-cells. This mechanism allows for the direct activation of T-cells and their anti-tumor features, ultimately resulting in the lysis of tumor cells. In 2014, the FDA approved blinatumomab, a TCE directed to CD3 and CD19 for treatment of acute lymphoblastic leukemia. Since then, numerous TCEs have been developed, allowing for treating different hematological malignancies such as acute myeloid leukemia, multiple myeloma, and non-Hodgkin lymphoma and Hodgkin lymphoma. As of November 2023, seven clinically approved TCE therapies are on the market. TCE-based therapies still have their limitations; however, improving the properties of TCEs, as well as combining TCE-based therapies...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research